DK2935303T3 - 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV - Google Patents

4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV Download PDF

Info

Publication number
DK2935303T3
DK2935303T3 DK13864403.4T DK13864403T DK2935303T3 DK 2935303 T3 DK2935303 T3 DK 2935303T3 DK 13864403 T DK13864403 T DK 13864403T DK 2935303 T3 DK2935303 T3 DK 2935303T3
Authority
DK
Denmark
Prior art keywords
fluoronucleotides
fluoronucleosides
hcv
analogues
treatment
Prior art date
Application number
DK13864403.4T
Other languages
Danish (da)
English (en)
Inventor
Leonid Beigelman
Guangyi Wang
David Bernard Smith
Original Assignee
Janssen Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biopharma Inc filed Critical Janssen Biopharma Inc
Application granted granted Critical
Publication of DK2935303T3 publication Critical patent/DK2935303T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK13864403.4T 2012-12-21 2013-12-19 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV DK2935303T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745466P 2012-12-21 2012-12-21
US201361890125P 2013-10-11 2013-10-11
PCT/US2013/076740 WO2014100505A1 (en) 2012-12-21 2013-12-19 Substituted nucleosides, nucleotides and analogs thereof

Publications (1)

Publication Number Publication Date
DK2935303T3 true DK2935303T3 (da) 2021-05-03

Family

ID=50975302

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13864403.4T DK2935303T3 (da) 2012-12-21 2013-12-19 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV

Country Status (31)

Country Link
US (12) US9249174B2 (enExample)
EP (3) EP3421482A1 (enExample)
JP (4) JP6284547B2 (enExample)
KR (4) KR102532198B1 (enExample)
CN (2) CN105073766A (enExample)
AP (1) AP2015008533A0 (enExample)
AU (3) AU2013361200A1 (enExample)
BR (1) BR112015014457A2 (enExample)
CA (1) CA2894542C (enExample)
CL (2) CL2015001699A1 (enExample)
CY (1) CY1124742T1 (enExample)
DK (1) DK2935303T3 (enExample)
EA (1) EA201590943A1 (enExample)
EC (1) ECSP15031144A (enExample)
ES (1) ES2865402T3 (enExample)
GE (1) GEP201706757B (enExample)
HR (1) HRP20210510T1 (enExample)
HU (1) HUE053946T2 (enExample)
IL (3) IL296551B2 (enExample)
LT (1) LT2935303T (enExample)
MX (1) MX2015007925A (enExample)
PE (1) PE20151433A1 (enExample)
PH (1) PH12015501423A1 (enExample)
PL (1) PL2935303T3 (enExample)
PT (1) PT2935303T (enExample)
RS (1) RS61767B1 (enExample)
SG (2) SG10201802325TA (enExample)
SI (1) SI2935303T1 (enExample)
SM (1) SMT202100259T1 (enExample)
TW (2) TW201900182A (enExample)
WO (1) WO2014100505A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
BR112013001553B1 (pt) 2010-07-22 2021-01-12 Gilead Sciences, Inc. compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012088155A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
GEP20166496B (en) 2011-12-22 2016-06-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
WO2014100498A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP3421482A1 (en) * 2012-12-21 2019-01-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US9504705B2 (en) 2013-04-05 2016-11-29 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
US20180200280A1 (en) * 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
CN105307662B (zh) 2013-05-16 2019-06-04 里博科学有限责任公司 4’-氟-2’-甲基取代的核苷衍生物
EP3424938B1 (en) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. 4'-azidoalkyl-substituted nucleosides, nucleotides and analogs thereof
WO2014209979A1 (en) 2013-06-26 2014-12-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN105594149B (zh) * 2013-10-04 2019-04-09 Lg 电子株式会社 终端在无线通信系统中发送ack/nack的方法及其设备
CN113712989A (zh) 2013-10-11 2021-11-30 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
PE20170203A1 (es) 2014-02-06 2017-03-16 Riboscience Llc Derivados de nucleosido sustituidos con 4'-difluorometilo como inhibidores de la replicacion de arn de la influeza
BR112016029612B1 (pt) 2014-06-17 2021-01-19 Pfizer Inc. compostos de di-hidroisoquinolinona substituídos
EA201692537A1 (ru) 2014-06-24 2017-05-31 Элиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
EP3160979A4 (en) * 2014-06-24 2018-01-03 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
ES2841310T3 (es) 2014-06-24 2021-07-08 Janssen Biopharma Inc Nucleósidos, nucleótidos y análogos sustituidos para su uso en el tratamiento de infecciones virales
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
CN104478976A (zh) * 2014-11-12 2015-04-01 苏州明锐医药科技有限公司 索非布韦的制备方法
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) * 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
WO2016134054A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
DK3265102T3 (da) 2015-03-06 2025-10-13 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling
CN107531717B (zh) 2015-03-11 2021-07-27 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
CN106146433B (zh) * 2015-03-26 2019-04-26 常州制药厂有限公司 一种索非布韦的中间体的制备方法
MX2018002707A (es) * 2015-09-02 2018-08-01 Abbvie Inc Derivados de tetrahidrofurano antivirales.
ES2918585T3 (es) 2015-09-16 2022-07-19 Gilead Sciences Inc Métodos para el tratamiento de infecciones por el virus Arenaviridae
FI3433257T3 (fi) 2016-03-24 2024-01-08 Novartis Ag Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä
EP3448392A4 (en) * 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
CN107337702B (zh) * 2016-04-29 2021-11-05 江苏豪森药业集团有限公司 结晶型hcv抑制剂及其制备方法和应用
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN106083773B (zh) * 2016-05-31 2019-06-14 杭州惠诺医药科技有限公司 3,5-二苯甲酰基-2-去氧-2-氟-2-甲基-D-核糖-γ-内酯的制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018017994A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination drug treatment for hepatitis c infection
EP3497111A2 (en) 2016-08-12 2019-06-19 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
HRP20250266T1 (hr) 2017-02-01 2025-04-25 Atea Pharmaceuticals, Inc. Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CN111194217B (zh) * 2017-09-21 2024-01-12 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
CN111655268B (zh) 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
CN119633010A (zh) * 2018-03-07 2025-03-18 埃默里大学 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
WO2019237297A1 (en) * 2018-06-14 2019-12-19 Janssen Pharmaceuticals, Inc. Processes for preparing compounds/intermediates useful in the treatment of viral infections
WO2020219464A1 (en) * 2019-04-22 2020-10-29 Ligand Pharmaceuticals, Inc. Cyclic phosphate compounds
CA3142283A1 (en) * 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
WO2021140471A1 (en) * 2020-01-10 2021-07-15 Janssen Biopharma, Inc. Method for synthesis of 2'-alkyl- or 2'-alkenyl- or 2'-alkynyl-4'-fluoro-adenosine derivatives and intermediates thereof
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
CN118598916A (zh) 2020-02-18 2024-09-06 吉利德科学公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2021234308C1 (en) 2020-03-12 2024-02-22 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
JP7482250B2 (ja) 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
PL4157272T3 (pl) 2020-05-29 2025-10-20 Gilead Sciences, Inc. Remdesiwir do leczenia zakażeń wirusowych
TWI819321B (zh) 2020-06-24 2023-10-21 美商基利科學股份有限公司 1'-氰基核苷類似物及其用途
WO2022046631A1 (en) 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN117120444A (zh) 2021-04-16 2023-11-24 吉利德科学公司 使用酰胺制备卡巴核苷的方法
CN113234102A (zh) * 2021-05-18 2021-08-10 宁波大学 一种三配位磷衍生物及中间体及制备方法
EP4355319A4 (en) 2021-06-17 2025-01-22 ATEA Pharmaceuticals, Inc. BENEFICIAL ANTI-HCV COMBINATION THERAPY
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
TWI867455B (zh) 2022-03-02 2024-12-21 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
WO2023202604A1 (zh) 2022-04-20 2023-10-26 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US112966A (en) * 1871-03-21 Improvement in hay and cotton-presses
US3817978A (en) 1971-06-16 1974-06-18 Syntex Inc 4-fluoro nucleosides and sugar intermediates, and methods of preparing
US3852267A (en) 1972-08-04 1974-12-03 Icn Pharmaceuticals Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
DE3239986A1 (de) 1982-10-28 1984-05-03 Robert Bosch Gmbh, 7000 Stuttgart Handwerkzeugmaschine mit einem kreisscheibenfoermigen werkzeug
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5679342A (en) 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
IN167775B (enExample) 1988-06-24 1990-12-22 Hoechst India
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DE3932052A1 (de) 1989-09-26 1991-04-04 Basf Ag Oxazol- bzw. thiazolcarbonsaeureamide
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JP2889408B2 (ja) 1991-09-17 1999-05-10 富士写真フイルム株式会社 アゾメチン化合物及びこれを含有する熱転写色素供与材料
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
AU729657B2 (en) 1992-05-11 2001-02-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
DE4232852A1 (de) 1992-09-30 1994-03-31 Bayer Ag Imidazolinyl-pyridazine
ZA943999B (en) 1993-06-09 1995-02-03 Lonza Ag Quaternary ammonium and waterproofing/preservative compositions
IL111011A0 (en) 1993-09-22 1994-11-28 Wellcome Found Bisbenzimidazole compounds, their preparation and pharmaceutical compositions containing them
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
JPH07242544A (ja) 1994-03-01 1995-09-19 Takeda Chem Ind Ltd 抗腫瘍剤
SK283342B6 (sk) 1996-01-23 2003-06-03 Icn Pharmaceuticals Použitie ribavirínu na prípravu farmaceutického prostriedku
CZ120699A3 (cs) 1996-10-16 1999-09-15 Icn Pharmaceuticals, Inc. Monocyklická L-nukleosidová analoga a jejich využití
JP2001524936A (ja) 1996-10-16 2001-12-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド プリンｌ―ヌクレオシド類およびその用途
NZ503765A (en) 1997-09-12 2002-04-26 Exiqon As Bi-cyclic and tri-cyclic nucleotide analogues
BR9908270A (pt) 1998-02-25 2004-06-29 Univ Emory 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
WO1999061583A2 (en) 1998-05-28 1999-12-02 Incara Pharmaceuticals Corp. Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction
DE19855963A1 (de) 1998-12-04 2000-06-08 Herbert Schott Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
JP2002543214A (ja) 1999-05-04 2002-12-17 エクシコン エ／エス Ｌ−リボ−ｌｎａ類縁体
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process
EP2251015B1 (en) 2000-10-18 2013-02-20 Gilead Pharmasset LLC Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
RS50236B (sr) * 2001-01-22 2009-07-15 Merck & Co.Inc., Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
US20040006002A1 (en) 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
AT411065B (de) 2001-12-27 2003-09-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von heterocyclischen (r)- und (s)-cyanhydrinen
JP2005527499A (ja) 2002-02-13 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド ヌクレオシド化合物を用いてオルトポックスウイルスの複製を阻害する方法
US20120041184A1 (en) 2002-02-20 2012-02-16 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003213628A1 (en) 2002-02-28 2003-09-16 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
WO2003099840A1 (en) 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
JP2006512288A (ja) 2002-06-27 2006-04-13 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US20060264389A1 (en) 2002-07-16 2006-11-23 Balkrishen Bhat Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004014312A2 (en) 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US7393954B2 (en) 2002-12-12 2008-07-01 Reliable Biopharmaceutical Corporation Process for the production of pentostatin aglycone and pentostatin
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
EP1620408A2 (en) 2003-04-16 2006-02-01 F. Hoffmann-La Roche Ag Quinazoline compounds
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2005020884A2 (en) * 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
PL2604620T5 (pl) * 2003-05-30 2024-10-14 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydu
US7507859B2 (en) 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
AU2004269026B2 (en) 2003-08-27 2010-02-25 Biota Scientific Management Pty Ltd Novel tricyclic nucleosides or nucleotides as therapeutic agents
CA2542077A1 (en) 2003-10-08 2005-04-21 President And Fellows Of Harvard College Pyrovalerone analogs and therapeutic uses thereof
AU2005256963A1 (en) 2004-06-23 2006-01-05 Centre National De La Recherche Scientifique 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
JP5080973B2 (ja) 2004-06-24 2012-11-21 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルスの感染を処置するためのヌクレオシドアリールホスホルアミダート
EP1828217A2 (en) 2004-12-16 2007-09-05 Febit Biotech GmbH Polymerase-independent analysis of the sequence of polynucleotides
JP2008532950A (ja) 2005-03-08 2008-08-21 バイオタ サイエンティフィック マネージメント ピーティーワイ リミテッド 治療薬としての二環式ヌクレオシドおよび二環式ヌクレオチド
JP2008535932A (ja) 2005-03-09 2008-09-04 イデニクス（ケイマン）リミテツド 抗ウィルス剤としての非天然塩基を有するヌクレオシド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
EP1877054A2 (en) 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US8207136B2 (en) 2005-04-26 2012-06-26 The Board Of Trustees Of The University Of Illinois Nucleoside compounds and methods of use thereof
EP1928475B1 (en) 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
JP2009532448A (ja) 2006-04-03 2009-09-10 アストラゼネカ アクチボラグ 置換アデニンおよびそれらの使用
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
ATE493428T1 (de) 2006-10-10 2011-01-15 Medivir Ab Hcv-nukleosidinhibitor
US20120135091A1 (en) 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
AU2008210411A1 (en) 2007-01-31 2008-08-07 Alios Biopharma, Inc. 2-5A derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
JP2008214305A (ja) 2007-03-07 2008-09-18 Kotobuki Seiyaku Kk 置換アミン誘導体及びこれを有効成分とする医薬組成物
WO2008117047A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20080255038A1 (en) 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
EP1980568A1 (de) 2007-04-13 2008-10-15 Eberhard Karls Universität Tübingen Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung
PL2014771T3 (pl) 2007-06-25 2015-05-29 Anadys Pharmaceuticals Inc Ciągły proces hydrolizy enzymatycznej
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
WO2009058800A2 (en) 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8293720B2 (en) 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
WO2009086201A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
WO2009086192A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
CN102083828B (zh) 2008-02-22 2013-11-13 Irm责任有限公司 作为c-kit和pdgfr激酶抑制剂的杂环化合物和组合物
US8415321B2 (en) 2008-04-15 2013-04-09 Raymond F. Schinazi Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
US20110171192A1 (en) 2008-09-05 2011-07-14 Hiroshi Tomiyama Substituted amine derivative and medicinal composition comprising same as the active ingredient
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EA019341B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
CN102395590A (zh) 2009-02-06 2012-03-28 Rfs制药公司 用于治疗癌症和病毒感染的嘌呤核苷单磷酸酯前药
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US20100240604A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
EP2408306A4 (en) 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CN102686599B (zh) * 2009-09-29 2016-10-05 杨森产品有限公司 核苷的氨基磷酸酯衍生物
US20150018301A1 (en) 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
JP2013522376A (ja) 2010-03-24 2013-06-13 メディカル ユニバーシティー オブ サウス カロライナ 変性疾患を治療するための組成物および方法
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
FR2960235B1 (fr) 2010-05-18 2013-11-01 Inst Francais Du Petrole Procede d'oligomerisation des olefines utilisant une composition comprenant un complexe organometallique contenant un ligand alcoxy fonctionnalise par un hetero-atome.
FR2960234B1 (fr) 2010-05-18 2013-11-01 Inst Francais Du Petrole Procede de dimerisation de l'ethylene en butene-1 utilisant une composition comprenant un complexe a base de titane et un ligand alcoxy fonctionnalise par un hetero-atome.
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
BR112013001553B1 (pt) 2010-07-22 2021-01-12 Gilead Sciences, Inc. compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem
WO2012016713A1 (en) 2010-08-05 2012-02-09 Ruprecht-Karls-Universität Heidelberg Tumour targeting with polypeptides
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
CA2812962C (en) 2010-09-22 2020-03-31 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
AR083221A1 (es) 2010-09-29 2013-02-06 Univ Nac Quilmes Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
US20120082795A1 (en) 2010-10-01 2012-04-05 Ppg Industries Ohio, Inc. Method for using a primer comprising a self-emulsified polyester microgel
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
WO2012088155A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
WO2012099630A1 (en) 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2012161799A1 (en) 2011-02-24 2012-11-29 Georgia Health Sciences University Research Institute, Inc Epidithiodioxopiperazines and uses thereof in treating cancer
EP2697241B1 (en) 2011-04-13 2019-06-12 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012167133A2 (en) 2011-06-01 2012-12-06 The Regents Of The University Of California Inhibitors of anandamide transport and their therapeutic uses
FR2977586B1 (fr) 2011-07-08 2013-07-12 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
DE102011108874A1 (de) 2011-07-28 2013-01-31 Hydac System Gmbh Steuervorrichtung
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
US8575119B2 (en) 2011-09-23 2013-11-05 Enanta Pharmaceuticals, Inc. 2′-chloroacetylenyl substituted nucleoside derivatives
CN103102345B (zh) 2011-11-14 2015-06-03 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
FR2982858B1 (fr) 2011-11-18 2013-11-29 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
FR2984322B1 (fr) 2011-12-16 2013-12-20 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
PT2794629T (pt) * 2011-12-20 2017-07-20 Riboscience Llc Derivados de nucleósidos substituídos em 2¿-4¿-difluor-2¿-metilo, como inibidores da replicação do arn de vhc (vírus da hepatite c)
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
GEP20166496B (en) 2011-12-22 2016-06-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2013138210A1 (en) 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ629428A (en) 2012-03-21 2016-10-28 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
CN104470939B (zh) 2012-05-22 2017-04-26 埃迪尼克斯医药有限责任公司 用于肝脏疾病的d型氨基酸化合物
EP2676987A1 (en) 2012-06-21 2013-12-25 Universidad De Burgos Cross-linked aramid
CN104583224A (zh) 2012-07-03 2015-04-29 百时美施贵宝公司 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法
KR20150046259A (ko) 2012-08-23 2015-04-29 앨리오스 바이오파마 인크. 파라믹소바이러스 바이러스성 감염의 치료용 화합물
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
US9388142B2 (en) 2012-09-26 2016-07-12 Merck Patent Gmbh Quinazolinone derivatives as PARP inhibitors
KR102281288B1 (ko) 2012-09-26 2021-07-26 에프. 호프만-라 로슈 아게 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
EP2912050A4 (en) 2012-10-29 2016-09-28 Cocrystal Pharma Inc PYRIMIDIN NUCLEOTIDES AND THEIR MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
JP2016503797A (ja) 2012-12-20 2016-02-08 アルデイラ セラピューティクス， インコーポレイテッド ペリ−カルビノール
HRP20182037T1 (hr) 2012-12-21 2019-02-08 Epizyme, Inc. Inhibitori prmt5 i njihova uporaba
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
WO2014100498A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201503526UA (en) 2012-12-21 2015-06-29 Sanofi Sa Dual glp1/gip or trigonal glp1/gip/glucagon agonists
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
EP3421482A1 (en) * 2012-12-21 2019-01-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
LT2935312T (lt) 2012-12-21 2018-10-25 F. Hoffmann-La Roche Ag Peptidai, kaip oksitocino agonistai
KR20150100814A (ko) 2012-12-21 2015-09-02 콴티셀 파마슈티컬스, 인크. 히스톤 데메틸라제 억제제
BR112015014752B1 (pt) 2012-12-21 2022-07-05 Plexxikon, Inc Compostos e seus uso para modulação de cinase
LU92126B1 (fr) 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
ES2649473T3 (es) 2013-03-04 2018-01-12 Bayer Animal Health Gmbh Derivados de N-[3-(1H-pirazol-4-il)fenilmetil]-sulfonamida sustituidos con halógeno y compuestos relacionados como pesticidas para uso en protección vegetal, medicina veterinaria y protección de materiales
US20140309413A1 (en) 2013-03-11 2014-10-16 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
US9504705B2 (en) 2013-04-05 2016-11-29 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
CN105307662B (zh) 2013-05-16 2019-06-04 里博科学有限责任公司 4’-氟-2’-甲基取代的核苷衍生物
EP3424938B1 (en) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. 4'-azidoalkyl-substituted nucleosides, nucleotides and analogs thereof
WO2014209979A1 (en) * 2013-06-26 2014-12-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6485817B2 (ja) 2013-08-21 2019-03-20 ヤンセン バイオファーマ インク． 抗ウイルス化合物
EP3030566B1 (en) 2013-09-12 2020-07-08 Janssen BioPharma, Inc. 7,8-dihydro-3h-pyrazino[1,2-b]pyridazine-3,5(6h)-dione compounds and uses thereof
DK3030549T3 (da) 2013-09-12 2019-05-13 Janssen Biopharma Inc Pyridazinonforbindelser og anvendelser deraf
CN113712989A (zh) 2013-10-11 2021-11-30 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
ES2841310T3 (es) * 2014-06-24 2021-07-08 Janssen Biopharma Inc Nucleósidos, nucleótidos y análogos sustituidos para su uso en el tratamiento de infecciones virales
EA201692537A1 (ru) 2014-06-24 2017-05-31 Элиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
WO2016014398A1 (en) 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
RU2017106742A (ru) 2014-08-05 2018-09-06 Элиос Биофарма, Инк. Комбинированная терапия для лечения парамиксовируса
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
CN107531717B (zh) 2015-03-11 2021-07-27 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
JP6860585B2 (ja) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク． 非環状抗ウイルス 優先出願の参照による組み込み
WO2017156407A1 (en) 2016-03-10 2017-09-14 Alios Biopharma, Inc. Method of preparing aza-pyridone compounds
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
WO2018222774A1 (en) 2017-05-30 2018-12-06 Alios Biopharma, Inc. Methods for treating pneumoviruses
JP2022512397A (ja) 2018-12-12 2022-02-03 ヤンセン バイオファーマ インク． 抗ウイルス薬としてのシクロペンチルヌクレオシド類似体
BR112021010236A2 (pt) 2018-12-12 2021-08-24 Janssen Biopharma, Inc. Análogos de ciclobutil nucleosídeos como antivirais

Also Published As

Publication number Publication date
AU2013361200A1 (en) 2015-07-23
CL2015001699A1 (es) 2015-10-30
US20160016987A1 (en) 2016-01-21
EP2935303A4 (en) 2016-08-10
US20140179627A1 (en) 2014-06-26
JP2022180507A (ja) 2022-12-06
PH12015501423A1 (en) 2015-09-14
JP6637023B2 (ja) 2020-01-29
US10112966B2 (en) 2018-10-30
CA2894542C (en) 2023-10-31
HUE053946T2 (hu) 2021-08-30
US10487104B2 (en) 2019-11-26
AU2018203337A1 (en) 2018-05-31
US20200079813A1 (en) 2020-03-12
EA201590943A1 (ru) 2016-01-29
KR102168621B1 (ko) 2020-10-22
CN110684067A (zh) 2020-01-14
LT2935303T (lt) 2021-03-25
US20190031703A1 (en) 2019-01-31
IL274901B (en) 2022-10-01
AU2020200499B2 (en) 2021-05-06
KR20150100806A (ko) 2015-09-02
ECSP15031144A (es) 2015-11-30
EP2935303B1 (en) 2021-02-17
SG10201802325TA (en) 2018-04-27
EP3421482A1 (en) 2019-01-02
CN105073766A (zh) 2015-11-18
ES2865402T3 (es) 2021-10-15
JP2018080178A (ja) 2018-05-24
KR20200120776A (ko) 2020-10-21
AU2020200499A1 (en) 2020-02-13
JP2016505595A (ja) 2016-02-25
SMT202100259T1 (it) 2021-07-12
HRP20210510T1 (hr) 2021-05-14
IL239324A0 (en) 2015-07-30
US20170037075A1 (en) 2017-02-09
HK1216536A1 (en) 2016-11-18
GEP201706757B (en) 2017-10-25
US20140179910A1 (en) 2014-06-26
JP2020063284A (ja) 2020-04-23
CA2894542A1 (en) 2014-06-26
KR20210141773A (ko) 2021-11-23
PT2935303T (pt) 2021-04-30
US20160039858A1 (en) 2016-02-11
BR112015014457A2 (pt) 2017-11-21
SG11201504554UA (en) 2015-07-30
US9249174B2 (en) 2016-02-02
PE20151433A1 (es) 2015-10-16
RS61767B1 (sr) 2021-05-31
US12173025B2 (en) 2024-12-24
IL296551B1 (en) 2023-12-01
IL274901B2 (en) 2023-02-01
US10793591B2 (en) 2020-10-06
IL296551A (en) 2022-11-01
US9243022B2 (en) 2016-01-26
US20230167151A1 (en) 2023-06-01
SI2935303T1 (sl) 2021-08-31
US11485753B2 (en) 2022-11-01
US10144755B2 (en) 2018-12-04
US20170037077A1 (en) 2017-02-09
US20210139523A1 (en) 2021-05-13
TW201900182A (zh) 2019-01-01
KR102327888B1 (ko) 2021-11-17
AU2018203337B2 (en) 2019-12-05
TWI641615B (zh) 2018-11-21
KR102532198B1 (ko) 2023-05-11
EP3912984A1 (en) 2021-11-24
AP2015008533A0 (en) 2015-06-30
JP6284547B2 (ja) 2018-02-28
JP7196054B2 (ja) 2022-12-26
US10683320B2 (en) 2020-06-16
IL274901A (en) 2020-07-30
KR102788773B1 (ko) 2025-03-28
WO2014100505A1 (en) 2014-06-26
MX2015007925A (es) 2015-10-05
US20190085011A1 (en) 2019-03-21
TW201429983A (zh) 2014-08-01
KR20230069261A (ko) 2023-05-18
EP2935303A1 (en) 2015-10-28
PL2935303T3 (pl) 2021-10-04
US20160024136A1 (en) 2016-01-28
CY1124742T1 (el) 2022-07-22
IL239324B (en) 2020-11-30
CL2017001769A1 (es) 2018-02-16
IL296551B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
EP3313989C0 (en) MODIFIED CRISPR RNA AND MODIFIED SINGLE CRISPR RNA AND USES THEREOF
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK2800565T3 (da) Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK2699553T3 (da) Substituerede diaminocarboxamid- og diaminocarbonitrilpyrimidiner, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2943192T3 (da) Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin
DK2996473T3 (da) Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK3828277T3 (da) Sammensætninger, fremgangsmåder og apparatur til syntese af oligonukleotider
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
EP2714059A4 (en) TREATMENT OF PAIN USING PLACENTARIAN STEM CELLS
IL254251A0 (en) Human fibrolamellar hepatocellular carcinomas (hfl-hccs)
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK2861273T3 (da) Anvendelse af heparin og kulhydrater til behandling af cancer.
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte